High-dose rituximab with chemotherapy for men with advanced lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a higher dose of rituximab combined with standard chemotherapy (CHOP) for men with newly diagnosed advanced large B-cell lymphoma. The goal is to see if the higher dose can control the cancer better than the standard approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man under 75 years old.
- You must have a type of lymphoma called diffuse large B-cell lymphoma (DLBCL).
- Your lymphoma must be at an advanced stage (stage III or IV).
- You must not have had any previous treatment for lymphoma, such as chemotherapy or radiation.
- Your organs and blood counts must be healthy enough to safely receive the treatment.
- You must agree to use reliable birth control for 12 months after receiving the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, rituximab and CC-99282, as a first treatment for older adults with diffuse large b-cell lymphoma who are too frail for standard chemotherapy. The goal is to see if this gentler approach can effectively control the disease while being easier to tolerate.
This trial tests whether adding an extra targeted drug (called X) to the standard chemo (Pola-R-CHP) can help people with aggressive B-cell lymphoma that didn't respond well after the first round. It aims to improve outcomes for those who need a stronger treatment approach.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial is testing a new combination of immunotherapy (sintilimab and rituximab) followed by standard chemotherapy (R-CHOP) for people with untreated primary mediastinal B-cell lymphoma (PMBCL). It aims to see if this approach can improve outcomes for this specific type of lymphoma.
This study tests a new treatment combination (CD-RCHOP, likely a form of chemotherapy with an antibody) for people with a high-risk type of diffuse large B-cell lymphoma that has certain genetic changes (TP53 mutation and 17p deletion). It aims to see if this approach is safe and effective for this specific group.
Hear when a new Lymphoma, Large B-Cell, Diffuse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.